A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
NCT06069726
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Glioblastoma
Interventions
DRUG:
Atezolizumab
Sponsor
Duke University